Expression of HLA and accessory molecules of mature bulk PBDCs obtained from MM patients and healthy donors
| . | MM patients . | Healthy donors . |
|---|---|---|
| HLA-class I | 551 ± 237.7 | 570.3 ± 262.5 |
| HLA-class II DR | 349.7 ± 107.3* | 738.3 ± 124.8 |
| CD40 | 18.3 ± 11.2* | 43.3 ± 10.5 |
| CD80 | 10.7 ± 4.5* | 29.5 ± 12.9 |
| CD86 | 201 ± 174.5 | 235.7 ± 208.6 |
| . | MM patients . | Healthy donors . |
|---|---|---|
| HLA-class I | 551 ± 237.7 | 570.3 ± 262.5 |
| HLA-class II DR | 349.7 ± 107.3* | 738.3 ± 124.8 |
| CD40 | 18.3 ± 11.2* | 43.3 ± 10.5 |
| CD80 | 10.7 ± 4.5* | 29.5 ± 12.9 |
| CD86 | 201 ± 174.5 | 235.7 ± 208.6 |
Mature bulk PBDCs were enriched as indicated in “Materials and methods.” After 72 hours from the beginning of PBMC culture, bulk DCs were gated as DR (+) lineage markers (−) cells. The phenotype of gated cells was further examined in 3-color flow cytometry analysis by plotting histograms for the expression of each indicated surface molecule. Data are expressed as mean values ± SD of mean fluorescence intensity after subtracting fluorescence intensity given by isotype-matched controls. Values have been calculated from 3 separate experiments conducted in parallel on PBDCs of one normal subject and one MM patient.
Data from the 2 groups were considered significantly different when P < .05.